Annovis Earnings Before Interest Taxes and Depreciation Amortization EBITDA Trend from 2010 to 2022

ANVS -  USA Stock  

USD 9.42  0.61  6.92%

Annovis Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA yearly trend continues to be relatively stable with very little volatility. Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop to -14,868,372. . Annovis Bio Operating Expenses is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Operating Expenses of 14.54 Million. As of 05/16/2022, Research and Development Expense is likely to grow to about 9.1 M, while Consolidated Income is likely to drop (14.9 M).
  
Refresh
Check Annovis Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Annovis main balance sheet or income statement drivers, such as Operating Expenses of 15.7 M, Research and Development Expense of 9.1 M or Selling General and Administrative Expense of 4.8 M, as well as many exotic indicators such as Book Value per Share of 6.3, Current Ratio of 32.94 or Debt to Equity Ratio of 0.0367. Annovis financial statements analysis is a perfect complement when working with Annovis Bio Valuation or Volatility modules. It can also supplement various Annovis Bio Technical models. Please continue to the analysis of Annovis Bio Correlation against competitors.

Annovis Earnings Before Interest Taxes and Depreciation Amortization EBITDA Breakdown

Showing smoothed Earnings Before Interest Taxes and Depreciation Amortization EBITDA of Annovis Bio with missing and latest data points interpolated. EBITDA is a non-GAAP accounting metric that is widely used when assessing the performance of companies; calculated by adding [DepAmor] back to Earning Before Interest and Taxes EBIT.Annovis Bio's Earnings Before Interest Taxes and Depreciation Amortization EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Annovis Bio's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (2.1 M)10 Years Trend
Decreasing
Slightly volatile
 Earnings Before Interest Taxes and Depreciation Amortization EBITDA 
Share
      Timeline 

Annovis Earnings Before Interest Taxes and Depreciation Amortization EBITDA Regression Statistics

Arithmetic Mean(3,251,915)
Coefficient Of Variation(161.01)
Mean Deviation 3,855,662
Median(713,937)
Standard Deviation 5,235,753
Range 14,154,435
R-Value(0.71)
R-Squared 0.50
Significance 0.006542
Slope(954,610)

Annovis Earnings Before Interest Taxes and Depreciation Amortization EBITDA History

2019-1 M
2020-5.5 M
2021-14.5 M
2022-14.9 M

About Annovis Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Annovis Bio income statement, its balance sheet, and the statement of cash flows. Annovis Bio investors use historical funamental indicators, such as Annovis Bio's Earnings Before Interest Taxes and Depreciation Amortization EBITDA, to determine how well the company is positioned to perform in the future. Although Annovis Bio investors may use each financial statement separately, they are all related. The changes in Annovis Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Annovis Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Annovis Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Annovis Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-14.5 M-14.9 M
Earnings before Tax-14.5 M-14.9 M
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 2 people.

Annovis Bio Investors Sentiment

The influence of Annovis Bio's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Annovis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Annovis Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Annovis Bio's short interest history, or implied volatility extrapolated from Annovis Bio options trading.

Current Sentiment - ANVS

Annovis Bio Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Annovis Bio. What is your sentiment towards investing in Annovis Bio? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Please continue to the analysis of Annovis Bio Correlation against competitors. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.